Background: Endogenous ligands of cannabinoid receptors (endocannabinoids), in particular anandamide (arachidonylethanolamide), have been recognized as being of crucial importance in a variety of physiological functions. Plasma concentrations of anandamide have been measured in a number of investigations; however, discrepant data on ''normal'' anandamide plasma concentrations were reported. Since this might be caused by pre-analytical variables, we investigated the impact of different sample handling conditions on measured plasma anandamide concentrations. Methods: Blood samples were taken from healthy volunteers in EDTA-or heparin-containing tubes; whole blood samples were kept at q48C, room temperature, or 378C, respectively, for up to 120 min before obtaining plasma by centrifugation. Plasma anandamide concentrations were measured by an isotope-dilution liquid chromatography tandem mass spectrometry (LC-MS/MS) method. Results: A marked time-and temperature-dependent increase in plasma anandamide concentrations ex vivo was observed in both EDTA-and heparin-containing tubes. Mean anandamide concentrations approximately doubled when EDTA samples were kept at 48C for 60 min before centrifugation wimme-
Introduction
In the early 1990s, two G-protein-coupled receptors binding D-9-tetrahydrocannabinol (THC), the major psychoactive component of marijuana, were characterized (CB1 and CB2) (1) (2) (3) . Subsequently, amides and esters of long-chain polyunsaturated fatty acids have been identified as endogenous ligands of cannabinoid receptors; among these ''endocannabinoids'', arachidonylethanolamide (synonym anandamide) seems to be the most important (4) (5) (6) .
During recent years, it has become evident that the interaction of endocannabinoids and CB receptors is part of fundamental regulatory mechanisms in numerous physiological processes.
CB 1 receptors have been found in most areas of the brain, generally with a presynaptic localization, where they play important roles in controlling neurotransmitter release (7, 8) . There is strong evidence that central endocannabinoid effects are involved in cognition, pain processing, mood, memory, control of food intake and energy balance, and in problem drug use (9) (10) (11) . Recently, rimonabant, a CB 1 receptor antagonist, has been introduced for the treatment of drug addiction and obesity-related disorders (12) . CB 2 receptors have been found primarily in peripheral locations, especially on immune and endothelial cells (3). CB 2 receptor-based peripheral endocannabinoid signaling is involved in regulation of the immune system (13) (14) (15) , apoptosis (16, 17) and vasomotor activity (18) (19) (20) . Recently, a link between common CB 2 receptor gene polymorphisms and autoimmune diseases was suggested (21) .
Endocannabinoid-inactivating enzymes, particularly fatty acid amide hydrolase (FAAH), have been proposed as therapeutic targets for a variety of diseases (22, 23) .
Plasma concentrations of anandamide have been studied in a number of investigations (24) (25) (26) (27) (28) (29) ; interestingly, wide variations of mean plasma anandamide concentrations were reported in cohorts of healthy volunteers we.g., Fernandez-Rodriguez et al. (27) , mean anandamide concentration 0.13 mg/L; De Marchi et al. (24) , mean concentration 0.9 mg/Lx (conversion of units for anandamide: wnmol/Lx=0.35™wmg/Lx; wmg/Lx=2.87™wnmol/Lx). In these studies, reliable and accurate isotope dilution mass spectrometry methods were applied, but the authors gave no detailed information on preanalytical sample handling. Since nucleated blood cells are known to be capable of both the release and metabolization of anandamide (30) , preanalytical variables may account for the discrepant observations on ''normal'' plasma anandamide con- centrations. Therefore, we decided to study the impact of these variables on plasma anandamide concentrations systematically.
Materials and methods

Analytical method
For anandamide quantification, we used a novel, semi-automated, isotope-dilution liquid chromatography tandem mass spectrometry (LC-MS/MS) method. A Waters Alliance 2795 HPLC module coupled to a Waters Micromass Quattro Ultima Pt MS/MS system (Waters, Milford, MA, USA) was used. For calibration, pure solutions of anandamide in methanol/ water were used (1-50 mg/L). As an internal standard, fourfold deuterium-labeled anandamide was synthesized as previously described (31) 
Experiments
In a first study, 12 healthy volunteers were included after written informed consent. Blood was collected by venipuncture into five EDTA-containing tubes (S-Monovette ᮋ EDTA; Sarstedt, Numbrecht, Germany). One of the tubes was centrifuged within 5 min after venipuncture and plasma was immediately frozen (y208C). Two tubes were kept at q48C and were centrifuged after 60 or 120 min, respectively, to obtain plasma, which was then frozen immediately. Two further tubes were kept at room temperature (22-258C) for 60 or 120 min before centrifugation. Thus, a significant time-and temperature-dependent increase in plasma anandamide concentrations was observed. This may be explained by the release of anandamide from circulating immune cells (19, 30) .
We suspected that this release might in part be the consequence of non-physiological stimulation of leukocytes due to calcium chelation by EDTA and a temperature below 378C in the sample tubes. Therefore, in a second set of experiments, we used heparin-anticoagulated whole blood samples (S-Monovette ᮋ Lithium-Heparin; Sarstedt) kept at q48C, room temperature, or 378C for 30, 60 and 120 min. In samples from five healthy volunteers, a time-and temperaturedependent increase in anandamide concentrations was again observed (Figure 3) . The most marked increase in anandamide concentrations was found in samples stored at 378C; at this temperature, a mean ''D anandamide'' of 7.5 mg/L (SD 1.4 mg/L) was observed between 30 and 120 min after venipuncture. Lactate dehydrogenase (LDH), aspartate aminotransferase (AST), alanine aminotransferase (ALT), potassium, and glucose were analyzed in the plasma samples obtained immediately and after incubation at 378C for 120 min, respectively. While glucose concentrations decreased by a mean of 19%, no significant changes in the concentrations of the other analytes were observed.
In a third set of experiments, whole blood samples from ten healthy volunteers were precipitated with a 4:1 mixture of methanol/zinc sulfate 50 g/L immediately after sampling (200 mL of whole blood and 200 mL of precipitation solution); after centrifugation, supernatants were analyzed for anandamide. In all cases the anandamide signal was below the predefined lower limit of detection (-0.5 mg/L).
To study the stability of anandamide in cell-free plasma, aliquots of six plasma samples obtained during the incubation experiments were kept at room temperature for 24 h prior to analysis (concentration range 2.0-14.0 mg/L). A decrease in mean anandamide concentration of 9.5% within 24 h was observed.
The investigation protocols for all experiments were approved by the institutional Review Board.
Results and discussion
We were able to demonstrate extensive release of anandamide from whole blood cells ex vivo. This release may result from mobilization of pre-existing anandamide from cellular structures of blood cells, from de novo synthesis and exocytosis of anandamide ex vivo by blood cells, or from a combination of both.
To clarify this issue, we precipitated whole blood samples by adding methanol immediately after venipuncture under the assumption that this procedure would block all metabolic processes and disintegrate cell membranes. After centrifugation, we found only trace concentrations of anandamide in the supernatant. It cannot be completely ruled out that anandamide in part undergoes co-precipitation with proteins in this experiment; however, our observation rather suggests de novo synthesis of anandamide than release of pre-existing anandamide to cause ex vivo increases in plasma anandamide concentrations.
We conclude from our results that the determination of baseline plasma anandamide concentrations has to follow strictly standardized pre-analytical protocols with immediate sample centrifugation. Even if this protocol is followed, it cannot be completely ruled out that anandamide is released into plasma during centrifugation.
Stasis, hypoxia, and the foreign surface of a sample tube may trigger anandamide synthesis and release from blood cells; the potential of leukocytes to form anandamide has been demonstrated previously (19, 30) . The in vivo baseline rate of anandamide synthesis in these cells under physiological conditions, however, remains uncertain. Besides preanalytical considerations, our data demonstrate that blood cells actually posses a very high anandamide release capacity in response to stressful stimuli; this may be of functional relevance for the peripheral CB 2 receptor-based endocannabinoid system (14) (15) (16) (17) (18) (19) (20) (21) .
Furthermore, our results demonstrate the feasibility of characterizing the anandamide release capacity of blood cells using a standardized ex vivo sequential plasma sampling protocol from incubated heparinized whole blood, providing a ''D anandamide'', e.g., between 30 and 120 min after venipuncture. During this time interval, we found a linear increase in anandamide concentrations in samples from healthy vol-unteers ( Figure 3) . We plan to use this sampling principle in further studies to investigate blood-cell anandamide synthesis capacity in health and different disease states.
